Drug Discovery and Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50

Black Diamond analysis highlights 22 new oncogenic HER2 driver mutations

By Brian Buntz | May 13, 2022

Black Diamond TherapeuticsOn the heels of announcing a restructuring plan that reduces its workforce by 30%, Black Diamond Therapeutics (Nasdaq:BDTX) has announced that its discovery engine was featured in the peer-reviewed Cancer Research journal.

The journal is published by American Association for Cancer Research (AACR).

A paper highlighted in the journal explained how the company’s Mutation-Allostery-Pharmacology (MAP) discovery engine identified and experimentally validated 22 new oncogenic HER2 driver mutations.

The paper is titled “Computational and Functional Analyses of HER2 Mutations Revealing Allosteric Activation Mechanisms and Altered Pharmacologic Effects.”

The analysis highlights work from researchers at Black Diamond Therapeutics and Foundation Medicine (Cambridge, Massachusetts), who used the MAP discovery engine to produce a list of 222 known and potential driver mutations from 820 single-nucleotide variants.

The scientists screened 111 using Ba/F3-retrovirus proliferation assays to obtain a list of 37 HER2 driver mutations. A total of 15 of those mutations were previously identified, while 22 were novel oncogenic mutations.

The researchers concluded that the discovery of the mutations could highlight the need for novel inhibitors targeting HER2-mutant cancers.

In addition, the paper described the pharmacological characterization of the HER2-driver mutations.

“These findings support our overall approach to cancer treatment by demonstrating the value and importance of oncogenicity prediction, biological validation, protein conformation-based drug design and MasterKey inhibitor development against mutation families,” said Elizabeth Buck, chief scientific officer of Black Diamond Therapeutics, in a news release.


Filed Under: Drug Discovery, Oncology
Tagged With: Black Diamond Therapeutics, discovery engine, HER2 driver mutations, Mutation-Allostery-Pharmacology
 

Tell Us What You Think! Cancel reply

You must be logged in to post a comment.

Related Articles Read More >

Lab facility
Massachusetts is competing for ARPA-H biomedical research center
Blockchain
Startup vies to get blockchain adoption in pharma off the ground
NIH National Institutes of Health
NIH licenses COVID-19 research technologies to WHO initiative
Seagen
Details emerge from incident that led Seagen’s CEO to take a leave of absence 

MEDTECH 100 INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.

Need Drug Discovery news in a minute?

We Deliver!
Drug Discovery & Development Enewsletters get you caught up on all the mission critical news you need. Sign up today.
Enews Signup
Drug Discovery and Development
  • MASSDEVICE
  • DEVICETALKS
  • Medical Design & Outsourcing
  • MEDICAL TUBING + EXTRUSION
  • MEDTECH 100
  • Medical Design Sourcing
  • Subscribe to our Free E-Newsletter
  • Contact Us
  • About Us
  • Advertise With Us
  • R&D World
  • Drug Delivery Business News
  • Pharmaceutical Processing World

Copyright © 2022 WTWH Media LLC. All Rights Reserved. The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media
Privacy Policy | Advertising | About Us

Search Drug Discovery & Development

  • Home Drug Discovery and Development
  • Drug Discovery
  • Genomics/Proteomics
  • Oncology
  • Neurological Disease
  • Infectious Disease
  • R&D 100 Awards
  • The Pharma 50